Skip to content
Peptigraph home
Shop Peptides50% off*

Does CJC-1295 with ipamorelin work?

Each peptide has been studied on its own, not as a blend: CJC-1295 raised growth hormone in healthy adults, while ipamorelin did not beat placebo in its one large trial.

GHRH + GHRP blendUpdated

Short answer

Each peptide has been studied on its own, not as a blend: CJC-1295 raised growth hormone in healthy adults, while ipamorelin did not beat placebo in its one large trial.[1]

The ipamorelin trial, in bowel surgery patients, found no significant difference from placebo on its efficacy measures.[2]

What the CJC-1295 studies measured

The CJC-1295 trials enrolled healthy adults and measured hormone levels rather than body composition.[1]

In young adult men the pulses of growth hormone kept their usual size and frequency while the baseline between pulses rose.[3]

What the ipamorelin studies measured

In healthy male volunteers ipamorelin produced a single short episode of growth hormone release that fell away quickly.[4]

A recent review says performance and physique uses lack regulatory approval and that product quality in unregulated supply is uncertain.[5]

More on CJC-1295 + Ipamorelin

ResultsStudy outcomes and when they were measured.CJC-1295 + Ipamorelin overview

Sources

  1. 1Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  2. 2Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  3. 3Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  4. 4Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  5. 5The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026

Found an error? Report a correction.